A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)

April 29, 2024 updated by: GlaxoSmithKline

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab

This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1700

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Australia
    • New South Wales
      • Macquarie University, New South Wales, Australia, 2109
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Claude Farah
        • Contact:
        • Contact:
      • Sydney, New South Wales, Australia, 2010
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Deborah Yates
        • Contact:
        • Contact:
      • Westmead, New South Wales, Australia, 2145
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • John Wheatley
        • Contact:
        • Contact:
    • Queensland
      • Cairns, Queensland, Australia, 4870
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stephen Vincent
        • Contact:
        • Contact:
      • South Brisbane, Queensland, Australia, 4101
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Simon Bowler
        • Contact:
        • Contact:
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hubertus Jersmann
      • Bedford Park, South Australia, Australia, 5042
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jeffrey John Bowden
      • North Adelaide, South Australia, Australia, 5006
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andrew Tai
      • Toorak Gardens, South Australia, Australia, 5065
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mon Ming (Michael) Chia
        • Contact:
        • Contact:
      • Woodville South, South Australia, Australia, 5011
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Antony Veale
        • Contact:
        • Contact:
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Francis Thien
        • Contact:
        • Contact:
      • Clayton, Victoria, Australia, 3168
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Philip Bardin
        • Contact:
        • Contact:
      • Fitzroy, Victoria, Australia, 3065
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Naghmeh Radhakrishna
      • Frankston, Victoria, Australia, 3199
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Joy Sha
        • Contact:
        • Contact:
      • Prahran, Victoria, Australia, 3181
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mark Ji-Liang Hew
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • John Blakey
        • Contact:
        • Contact:
  • Austria
      • Feldbach, Austria, 8330
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Robert Voves
        • Contact:
        • Contact:
      • Wien, Austria, 1130
        • Completed
        • GSK Investigational Site
  • Canada
      • Quebec, Canada, G1V 4W2
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Remi Gagnon
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Richard Leigh
      • Edmonton, Alberta, Canada, T5J 3S9
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Warren P. Ramesh
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 5K4
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marcel Mallet
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • George Philteos
        • Contact:
        • Contact:
      • Ottawa, Ontario, Canada, K1H 1E4
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • William Yang
        • Contact:
        • Contact:
      • Toronto, Ontario, Canada, M5G 1E2
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jason Lee
        • Contact:
        • Contact:
      • Toronto, Ontario, Canada, M5T 3A9
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kenneth Chapman
        • Contact:
        • Contact:
      • Windsor, Ontario, Canada, N8X 1T3
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Syed Anees
        • Contact:
        • Contact:
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nadim Srour
      • Pierrefonds, Quebec, Canada, H9H 4Y6
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Reza Alizadehfar
        • Contact:
        • Contact:
      • Quebec City, Quebec, Canada, G1V 4G5
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Andreanne Cote
        • Contact:
        • Contact:
      • Trois-Rivieres, Quebec, Canada, G8T 7A1
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pierre Alexandre Menard
  • Finland
      • Tampere, Finland, 33520
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jussi Karjalainen
        • Contact:
        • Contact:
      • Turku, Finland, 20521
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Maritta Kilpelainen
        • Contact:
        • Contact:
  • France
      • Amiens, France, 80000
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Youcef Douadi
        • Contact:
        • Contact:
      • Annecy Cedex, France, 74011
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Toufik Didi
      • Antony, France, 92160
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gilles Garcia
        • Contact:
        • Contact:
      • Besançon, France, 25030
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pauline-Marie Roux
      • Brest Cedex, France, 29609
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Christophe Leroyer
        • Contact:
        • Contact:
      • Brest cedex, France, 29609
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pierrick Cros
      • Caen, France, 14033
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Helen Fouquet
      • Cannes Cedex, France, 06414
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Fabien Rolland
      • Cholet, France, 49300
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Philippe Masson
        • Contact:
        • Contact:
      • Dijon Cedex, France, 21079
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Philippe Bonniaud
      • La Tronche, France, 38700
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Christel Saint-Raymond
        • Contact:
        • Contact:
      • Le Mans Cedex, France, 72037
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • François Goupil
        • Contact:
        • Contact:
      • Lille Cedex, France, 59037
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Antoine Deschildre
        • Contact:
        • Contact:
      • Lille cedex, France, 59037
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stephanie Fry
        • Contact:
        • Contact:
      • Lyon cedex 04, France, 69317
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gilles Devouassoux
        • Contact:
        • Contact:
      • Marseille, France, 13003.
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hervé Pegliasco
        • Contact:
        • Contact:
      • Marseille, France, 13015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Pascal Chanez
      • Montfermeil, France, 93370
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Cyril Maurer
        • Contact:
        • Contact:
      • Montivilliers, France, 76290
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bouchra Lamia
        • Contact:
        • Contact:
      • Montpellier Cedex 5, France, 34295
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Arnaud Bourdin
      • Nantes cedex, France, 44093
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • François-Xavier Blanc
      • Nice cedex 1, France, 06001
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Johana Pradelli
        • Contact:
        • Contact:
      • Paris, France, 75012
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stéphanie Wanin
        • Contact:
        • Contact:
      • Paris, France, 75014
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Frederique Aubourg
      • Paris Cedex 18, France, 75877
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Camille Taille
        • Contact:
        • Contact:
      • Paris cedex 15, France, 75015
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rola Abou Taam
        • Contact:
        • Contact:
      • Pontoise, France, 95303
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jean-François Boitiaux
        • Contact:
        • Contact:
      • Rouen cedex, France, 76031
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Guillaume Mahay
        • Contact:
        • Contact:
      • Strasbourg, France, 67091
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Naji Khayath
      • Suresnes, France, 92150
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Colas Tcherakian
      • Toulouse, France, 31059
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Laurent Guilleminault
        • Contact:
        • Contact:
      • Tours cedex 9, France, 37044
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sylvain Marchand-Adam
  • Germany
      • Berlin, Germany, 12203
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Thomas Schultz
        • Contact:
        • Contact:
      • Berlin, Germany, 10969
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Markus Becker
      • Berlin, Germany, 12159
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Oliver Noga
      • Bonn, Germany, 53127
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Dirk Skowasch
        • Contact:
        • Contact:
      • Hamburg, Germany, 20354
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Margret Jandl
      • Magdeburg, Germany, 39120
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gabriele Illies
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, Germany, 69126
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Felix Herth
        • Contact:
        • Contact:
    • Bayern
      • Aschaffenburg, Bayern, Germany, 63739
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Peter Rueckert
        • Contact:
        • Contact:
      • Landsberg, Bayern, Germany, 86899
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Heiner Steffen
      • München, Bayern, Germany, 81241
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rainald Fischer
        • Contact:
        • Contact:
      • Weissenburg, Bayern, Germany, 91781
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Torsten Sandvoss
    • Brandenburg
      • Fuerstenwalde, Brandenburg, Germany, 15517
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Athanasios Xanthopoulos
        • Contact:
        • Contact:
    • Hessen
      • Darmstadt, Hessen, Germany, 64283
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andreas Forster
      • Frankfurt, Hessen, Germany, 60389
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Claus Keller
        • Contact:
        • Contact:
      • Frankfurt, Hessen, Germany, 60596
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Andreas Eich
        • Contact:
        • Contact:
      • Neu isenburg, Hessen, Germany, 63263
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sabine Ballenberger
        • Contact:
        • Contact:
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30625
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tobias Welte
        • Contact:
        • Contact:
    • Nordrhein-Westfalen
      • Bonn, Nordrhein-Westfalen, Germany, 53119
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Thomas Ginko
        • Contact:
        • Contact:
      • Rheine, Nordrhein-Westfalen, Germany, 48431
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Frank Koesters
        • Contact:
        • Contact:
    • Rheinland-Pfalz
      • Koblenz, Rheinland-Pfalz, Germany, 56068
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Olaf Schmidt
        • Contact:
        • Contact:
      • Mainz, Rheinland-Pfalz, Germany, 55128
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stephanie Korn
        • Contact:
        • Contact:
    • Sachsen
      • Leipzig, Sachsen, Germany, 04207
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Regina Deckelmann
        • Contact:
        • Contact:
      • Leipzig, Sachsen, Germany, 04275
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gerhard Hoheisel
        • Contact:
        • Contact:
      • Leipzig, Sachsen, Germany, 04347
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Falk Brunner
    • Sachsen-Anhalt
      • Halle, Sachsen-Anhalt, Germany, 06120
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Wolfgang Schuette
        • Contact:
        • Contact:
      • Halle, Sachsen-Anhalt, Germany, 06108
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Peter Uwe Haase
        • Contact:
        • Contact:
    • Schleswig-Holstein
      • Geesthacht, Schleswig-Holstein, Germany, 21502
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Petra Mikloweit
        • Contact:
        • Contact:
      • Luebeck, Schleswig-Holstein, Germany, 23558
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Frank Eberhardt
        • Contact:
        • Contact:
      • Luebeck, Schleswig-Holstein, Germany, 23552
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Andrea Ludwig-Sengpiel
        • Contact:
        • Contact:
      • Schleswig, Schleswig-Holstein, Germany, 24837
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andreas Deimling
  • Ireland
      • Cork, Ireland, T12 DFK4
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Desmond Murphy
        • Contact:
        • Contact:
      • Dublin, Ireland, D08 NHY1
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Brian Kent
        • Contact:
        • Contact:
      • Dublin, Ireland
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Marcus Butler
        • Contact:
        • Contact:
  • Israel
      • Beer Sheva, Israel, 8410101
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yael Raviv
      • Haifa, Israel, 34362
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yochai Adir
        • Contact:
        • Contact:
      • Jerusalem, Israel, 91120
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Neville Berkman
      • Jerusalem, Israel, 91031
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gabriel Izbicki
        • Contact:
        • Contact:
      • Kfar Saba, Israel, 44281
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • David Shitrit
        • Contact:
        • Contact:
      • Petah Tikva, Israel, 49100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mordechai Reuben Kramer
        • Contact:
        • Contact:
      • Ramat-Gan, Israel, 52621
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael Peled
      • Tel Aviv, Israel, 64239
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Amir Barshai
        • Contact:
        • Contact:
      • Zrifin, Israel, 70300
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Benjamin Fox
        • Contact:
        • Contact:
  • Italy
      • Padova, Italy, 35128
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Andrea Vianello
    • Campania
      • Napoli, Campania, Italy, 80131
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Giuseppe Spadaro
        • Contact:
        • Contact:
      • Salerno, Campania, Italy, 84131
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Massimo Triggiani
        • Contact:
        • Contact:
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italy, 40138
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stefano Nava
        • Contact:
        • Contact:
      • Cona, Emilia-Romagna, Italy, 44124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alberto Papi
        • Contact:
        • Contact:
      • Modena, Emilia-Romagna, Italy, 41124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bianca Beghè
        • Contact:
        • Contact:
      • Reggio Emilia, Emilia-Romagna, Italy, 42100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Nicola Facciolongo
        • Contact:
        • Contact:
    • Friuli-Venezia-Giulia
      • Trieste, Friuli-Venezia-Giulia, Italy, 34139
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marco Confalonieri
    • Lazio
      • Roma, Lazio, Italy, 168
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Cristiano Caruso
        • Contact:
        • Contact:
    • Liguria
      • Genova, Liguria, Italy, 16132
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Giovanni Passalacqua
        • Contact:
        • Contact:
    • Lombardia
      • Bergamo, Lombardia, Italy, 24127
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Fabiano Di Marco
        • Contact:
        • Contact:
      • Brescia, Lombardia, Italy, 25123
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Laura Pini
      • Mantova, Lombardia, Italy, 46100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Maria Teresa Costantino
        • Contact:
        • Contact:
      • Milano, Lombardia, Italy, 20122
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Francesco Blasi
        • Contact:
        • Contact:
      • Milano, Lombardia, Italy, 20123
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sergio Harari
      • Milano, Lombardia, Italy, 20132
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lorenzo Dagna
      • Milano, Lombardia, Italy, 20162
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jan Schroeder
        • Contact:
        • Contact:
      • Pavia, Lombardia, Italy, 27100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Angelo Guido Corsico
    • Marche
      • Ancona, Marche, Italy, 60020
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Maria Beatrice Bilo
        • Contact:
        • Contact:
    • Piemonte
      • Torino, Piemonte, Italy, 10128
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Luisa Brussino
        • Contact:
        • Contact:
    • Puglia
      • Bari, Puglia, Italy, 70124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Luigi Macchia
        • Contact:
        • Contact:
    • Sardegna
      • Monserrato, Sardegna, Italy, 09042
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Stefano Del Giacco
      • Sassari, Sardegna, Italy, 7100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Pietro Pirina
        • Contact:
        • Contact:
    • Sicilia
      • Catania, Sicilia, Italy, 95123
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Raffaele Campisi
        • Contact:
        • Contact:
      • Palermo, Sicilia, Italy, 90127
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alida Benfante
    • Toscana
      • Firenze, Toscana, Italy, 50134
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Fabio Almerigogna
        • Contact:
        • Contact:
      • Pisa, Toscana, Italy, 56124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alessandro Celi
        • Contact:
        • Contact:
      • Siena, Toscana, Italy, 53100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Elena Bargagli
    • Umbria
      • Perugia, Umbria, Italy, 06156
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stefano Baglioni
        • Contact:
        • Contact:
    • Veneto
      • Treviso, Veneto, Italy, 31100
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Micaela Romagnoli
        • Contact:
        • Contact:
      • Verona, Veneto, Italy, 37134
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gianenrico Senna
        • Contact:
        • Contact:
  • Japan
      • Aichi, Japan, 454-8509
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Masahiro Hirose
        • Contact:
        • Contact:
      • Aichi, Japan, 470-1192
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sumito Isogai
      • Aichi, Japan, 489-8642
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tomoki Kimura
      • Akita, Japan, 010-8543
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Masahide Takeda
      • Ehime, Japan, 790-0024
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Norihiko Nakanishi
      • Fukuoka, Japan, 805-8508
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Taihei Yanagida
      • Fukuoka, Japan, 806-8501
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Taishi Harada
        • Contact:
        • Contact:
      • Fukuoka, Japan, 813-0017
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Junichiro Tezuka
      • Fukuoka, Japan, 830-0011
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Takashi Kinoshita
        • Contact:
        • Contact:
      • Fukuoka, Japan, 802-0052
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tetsuya Kawano
      • Fukuoka, Japan, 811-1394
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Takehito Fukushima
        • Contact:
        • Contact:
      • Fukushima, Japan, 960-1295
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Junpei Saito
      • Gifu, Japan, 509-6134
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroyuki Ohbayashi
      • Hiroshima, Japan, 734-8530
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nobuhisa Ishikawa
      • Hiroshima, Japan, 735-8585
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yojiro Onari
        • Contact:
        • Contact:
      • Hiroshima, Japan, 737-0023
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tadashi Senoo
        • Contact:
        • Contact:
      • Hokkaido, Japan, 053-8506
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yasutaka Kawai
      • Hokkaido, Japan, 064-0804
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroshi Tanaka
      • Hyogo, Japan, 650-0047
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Satoru Tsuruta
        • Contact:
        • Contact:
      • Hyogo, Japan, 653-0013
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Masahiro Kaneko
      • Ibaraki, Japan, 302-0022
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tomoyuki Ogata
        • Contact:
        • Contact:
      • Ibaraki, Japan, 319-1113
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Takefumi Saito
        • Contact:
        • Contact:
      • Ishikawa, Japan, 920-0293
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yutaka Takahara
      • Iwate, Japan, 020-8505
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yu Utsumi
        • Contact:
        • Contact:
      • Kagawa, Japan, 762-8550
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroyuki Nakamura
      • Kagoshima, Japan, 890-8520
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kentaro Machida
      • Kanagawa, Japan, 231-8682
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yoichi Nakamura
      • Kanagawa, Japan, 232-0024
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Makoto Kudo
      • Kanagawa, Japan, 236-0004
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yu Hara
        • Contact:
        • Contact:
      • Kanagawa, Japan, 236-0051
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shigeru Komatsu
      • Kanagawa, Japan, 254-8502
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yasuto Jin
        • Contact:
        • Contact:
      • Mie, Japan, 510-8561
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Masamichi Yoshida
        • Contact:
        • Contact:
      • Mie, Japan, 511-0061
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hisamichi Yuda
        • Contact:
        • Contact:
      • Mie, Japan, 515-8544
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Osamu Hataji
      • Miyagi, Japan, 981-8563
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tomohiro Sakakibara
      • Nagano, Japan, 386-8610
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Toshihiko Agatsuma
        • Contact:
        • Contact:
      • Niigata, Japan, 951-8520
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Toshiyuki Koya
      • Okayama, Japan, 701-0304
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Goro Kimura
        • Contact:
        • Contact:
      • Okayama, Japan, 702-8055
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nobukazu Fujimoto
      • Osaka, Japan, 530-0012
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tetsuya Ueda
        • Contact:
        • Contact:
      • Osaka, Japan, 543-8555
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yasuo Nishizaka
        • Contact:
        • Contact:
      • Osaka, Japan, 560-8552
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Keisuke Miki
        • Contact:
        • Contact:
      • Osaka, Japan, 569-1096
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hideo Kita
        • Contact:
        • Contact:
      • Osaka, Japan, 569-1192
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yasuhiro Funada
        • Contact:
        • Contact:
      • Osaka, Japan, 596-8501
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kenichi Takahashi
      • Osaka, Japan, 569-8686
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Takahiko Nakamura
      • Osaka, Japan, 572-8551
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Seiichi Nobuyama
      • Osaka, Japan, 593-8304
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Iwao Goma
      • Shimane, Japan, 693-8501
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Takeshi Isobe
        • Contact:
        • Contact:
      • Shizuoka, Japan, 420-8527
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Toshihiro Shirai
      • Shizuoka, Japan, 430-8525
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mikio Toyoshima
        • Contact:
        • Contact:
      • Tochigi, Japan, 321-0293
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shigemi Yoshihara
      • Tokyo, Japan, 103-0027
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Arihiro Kiyosue
      • Tokyo, Japan, 136-0075
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Koji Sugano
        • Contact:
        • Contact:
      • Tokyo, Japan, 141-8625
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kazuhiro Usui
      • Tokyo, Japan, 142-8666
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hironori Sagara
      • Tokyo, Japan, 150-8935
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Takehiro Izumo
        • Contact:
        • Contact:
      • Tokyo, Japan, 160-8582
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Koichi Fukunaga
      • Tokyo, Japan, 162-8655
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Motoyasu Iikura
        • Contact:
        • Contact:
      • Tokyo, Japan, 173-8606
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hiroyuki Nagase
        • Contact:
        • Contact:
      • Tokyo, Japan, 187-8510
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Yoshinobu Iwasaki
        • Contact:
        • Contact:
      • Tokyo, Japan, 190-0014
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mitsuhiro Kamimura
        • Contact:
        • Contact:
      • Tokyo, Japan, 204-8585
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Osamu Narumoto
      • Tokyo, Japan, 113-8431
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Norihiro Harada
      • Tokyo, Japan, 105-8471
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Takanori Numata
      • Tokyo, Japan, 113-8519
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yasunari Miyazaki
      • Tokyo, Japan, 173-0015
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hiroshi Yamamoto
      • Toyama, Japan, 930-8550
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Hirokazu Taniguchi
        • Contact:
        • Contact:
      • Wakayama, Japan, 640-8558
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tatsuyoshi Ikeue
        • Contact:
        • Contact:
  • Netherlands
      • Arnhem, Netherlands, 6815 AD
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Marjo van de Ven
        • Contact:
        • Contact:
      • Breda, Netherlands, 4818 CK
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Simone van der Sar
        • Contact:
        • Contact:
      • Deventer, Netherlands, 7416 SE
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Bas Langeveld
        • Contact:
        • Contact:
      • Eindhoven, Netherlands, 5623 EJ
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Pascal L.M.L. Wielders
        • Contact:
        • Contact:
      • Enschede, Netherlands, 7513 ER
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Helena P.A.A. van (Ilonka) Veen
        • Contact:
        • Contact:
      • Harderwijk, Netherlands, 3844 DG
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Stephanus J.M. Gans
        • Contact:
        • Contact:
      • Leeuwarden, Netherlands, 8934 AD
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Anneke ten Brinke
        • Contact:
        • Contact:
      • Nijmegen, Netherlands, 6532 SZ
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • R.J. (Jürgen) Hölters
        • Contact:
        • Contact:
      • Rotterdam, Netherlands, 3045 PM
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gert-Jan Braunstahl
        • Contact:
        • Contact:
      • Zwolle, Netherlands, 8025 AB
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kornelis W. Patberg
        • Contact:
        • Contact:
  • Norway
      • Bergen, Norway, 5021
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sverre Lehmann
        • Contact:
        • Contact:
      • Lørenskog, Norway, 1478
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gunnar Einvik
        • Contact:
        • Contact:
  • Portugal
      • Coimbra, Portugal, 3041-801
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Cláudia Chaves Loureiro
      • Guarda, Portugal, 6300-035
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Manuel Silva
      • Lisboa, Portugal, 1649-035
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ana Mendes
      • Matosinhos, Portugal, 4464-509
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ana Paula Vaz
      • Porto, Portugal, 4200-319
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • José Plácido
  • Puerto Rico
      • Guaynabo, Puerto Rico, 00968
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Alvaro U. Aranda
  • Slovenia
      • Golnik, Slovenia, 4204
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Peter Kopac
        • Contact:
        • Contact:
  • Spain
      • Alcorcón (Madrid), Spain, 28922
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ana Rosado Ingelmo
        • Contact:
        • Contact:
      • Almería, Spain, 04009
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • José Manuel Díaz López
      • Badalona, Spain, 08916
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Carlos Martínez Rivera
      • Barcelona, Spain, 08003
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • María del Pilar Ausin Herrero
        • Contact:
        • Contact:
      • Barcelona, Spain, 08035
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Xavier Muñoz Gall
        • Contact:
        • Contact:
      • Barcelona, Spain, 08036
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Irina Diana Bobolea
      • Barcelona, Spain, 8025
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • David Ramos Barbon
        • Contact:
        • Contact:
      • Barcelona, Spain, 08017
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Juan Roldan Sanchez
        • Contact:
        • Contact:
      • Basurto/Bilbao, Spain, 48013
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ignacio Antépara Ercoreca
      • Benalmádena, Spain, 29631
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gustavo De Luiz Martinez
        • Contact:
        • Contact:
      • Elche, Spain, 03293
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mónica Antón Girones
      • Esplugues de Llobregat, Spain, 08950
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jaime Lozano Blasco
      • Granada, Spain, 18014
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Concepción Morales García
        • Contact:
        • Contact:
      • Jerez de la Frontera, Spain, 11407
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Gregorio Soto Campos
      • Madrid, Spain, 28031
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ismael Ali García
        • Contact:
        • Contact:
      • Madrid, Spain, 28046
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • David Romero Ribate
        • Contact:
        • Contact:
      • Madrid, Spain, 28040
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • María del Mar Fernández Nieto
      • Madrid, Spain, 28041
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ismael García Moguel
        • Contact:
        • Contact:
      • Málaga, Spain, 29010
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • José Luis Velasco Garrido
      • Mérida (Badajoz), Spain, 06800
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Juan José Garrido Romero
        • Contact:
        • Contact:
      • Pamplona, Spain, 31008
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Pilar Cebollero Rivas
        • Contact:
        • Contact:
      • Salamanca, Spain, 37007
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jacinto Ramos González
      • Santander, Spain, 39008
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Juan Luis García Rivero
      • Santiago De Compostela. La Coruña., Spain, 15706
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Luis Valdés Cuadrado
      • Sán Crístobál De Lá Láguná, Spain, 38320
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ruperto González Pérez
      • Valencia, Spain, 46015
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Fernando José Sánchez-Toril López
        • Contact:
        • Contact:
      • Valencia, Spain, 46017
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Eva María Martínez Moragón
        • Contact:
        • Contact:
      • Via-Real (Castellón), Spain, 12540
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Patricia Sidro García
        • Contact:
        • Contact:
      • Vitoria - Gasteiz, Spain, 01009
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Marta Frías Jiménez
        • Contact:
        • Contact:
      • Zaragoza, Spain, 50009
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • José María Marín Trigo
    • Madrid
      • Pozuelo De Alarcón, Madrid, Spain, 28223
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Maria Echave-Sustaeta
  • Sweden
      • Linköping, Sweden, SE-58758
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mohanad Abbas
        • Contact:
        • Contact:
      • Lund, Sweden, SE-221 85
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Leif Bjermer
        • Contact:
        • Contact:
      • Stockholm, Sweden, SE-141 86
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Nikolaos Lazarinis
        • Contact:
        • Contact:
      • Uppsala, Sweden, SE-751 85
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Christer Janson
      • Östersund, Sweden, SE-831 83
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Nikolai Stenfors
        • Contact:
        • Contact:
  • Switzerland
      • Aarau, Switzerland, 5001
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hans Joachim Kabitz
      • Basel, Switzerland, 4031
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Michael A Tamm
        • Contact:
        • Contact:
      • Liestal, Switzerland, 4410
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Joerg Leuppi
        • Contact:
        • Contact:
      • St. Gallen, Switzerland, 9007
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Martin Brutsche
  • Taiwan
      • Changhua, Taiwan, 500
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ching-Hsiung Lin
      • Gueishan Township,Taoyuan County, Taiwan, 333
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Shu-Min Lin
      • Taichung, Taiwan, 404
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Chih-Yen Tu
        • Contact:
        • Contact:
      • Taichung, Taiwan, 40705
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Wei- Chang Huang
        • Contact:
        • Contact:
      • Taipei, Taiwan, 100
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ping-Hung Kuo
      • Taipei, Taiwan, 220
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Shih-Lung Cheng
        • Contact:
        • Contact:
  • United Kingdom
      • Belfast, United Kingdom, BT9 7AB
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Liam Heaney
      • Birmingham, United Kingdom, B9 5SS
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Adel Mansur
        • Contact:
        • Contact:
      • Bradford, United Kingdom, BD9 6RJ
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Dinesh Saralaya
        • Contact:
        • Contact:
      • Cottingham, East Yorkshire, United Kingdom, HU16 5JQ
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Shoaib Faruqi
        • Contact:
        • Contact:
      • Edinburgh, United Kingdom, EH16 4SA
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Roberto Rabinovich
      • Exeter., United Kingdom, EX2 5DW
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Matthew Masoli
        • Contact:
        • Contact:
      • Glasgow, United Kingdom, G31 2ER
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Douglas Cowan
        • Contact:
        • Contact:
      • Glasgow, United Kingdom, G51 4TF
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rekha Chaudhuri
        • Contact:
        • Contact:
      • London, United Kingdom, EC1A 7BE
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Paul Pfeffer
        • Contact:
        • Contact:
      • Newcastle Upon Tyne, United Kingdom, NE7 7DN
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Simon Doe
        • Contact:
        • Contact:
      • Oxford, United Kingdom, OX3 7LE
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ian Douglas Pavord
      • Portsmouth, United Kingdom, PO6 3LY
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Anoop Chauhan
      • Preston, United Kingdom, PR2 9HT
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kathryn Prior
        • Contact:
        • Contact:
      • Wakefield, United Kingdom, WF1 4DG
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • James Edward McCreanor
    • Gloucestershire
      • Bristol, Gloucestershire, United Kingdom, BS10 5NB
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • James Dodd
    • Lanarkshire
      • Airdrie, Lanarkshire, United Kingdom, ML6 0JS
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Andrew Smith
        • Contact:
        • Contact:
    • Merseyside
      • Liverpool, Merseyside, United Kingdom, L7 8XP
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Livingstone Chishimba
        • Contact:
        • Contact:
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Timothy Harrison
        • Contact:
        • Contact:
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35209
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Principal Investigator:
          • Weily Soong
        • Contact:
      • Mobile, Alabama, United States, 36608
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lawrence J Sindel
      • Scottsboro, Alabama, United States, 35768
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Younus Ismail
        • Contact:
        • Contact:
    • Arizona
      • Litchfield Park, Arizona, United States, 85340
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Connie Hsu
        • Contact:
        • Contact:
      • Phoenix, Arizona, United States, 85054
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sanjay Patel
      • Scottsdale, Arizona, United States, 85251
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Michael Everet Manning
        • Contact:
        • Contact:
    • California
      • Bakersfield, California, United States, 93301
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Tonny Tanus
        • Contact:
        • Contact:
      • Encinitas, California, United States, 92024
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Warren W Pleskow
        • Contact:
        • Contact:
      • Huntington Beach, California, United States, 92647
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Robby Ayoub
        • Contact:
        • Contact:
      • La Jolla, California, United States, 92307
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Brian Modena
      • Long Beach, California, United States, 90815
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kenneth T Kim
        • Contact:
        • Contact:
      • Los Angeles, California, United States, 90048
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • C. Andrew Schroeder
      • Newport Beach, California, United States, 92663
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ryan Mitchell Klein
      • Northridge, California, United States, 91324
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rami S El Yousef
      • Oxnard, California, United States, 93036
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Preeti Chopra
      • Rancho Cucamonga, California, United States, 91730
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Javier Chang
      • Redondo Beach, California, United States, 90277
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ulrike H.M Ziegner
        • Contact:
        • Contact:
      • Redwood City, California, United States, 94063
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Brian Lipson
      • San Diego, California, United States, 92123
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alexander Greiner
        • Contact:
        • Contact:
      • Santa Monica, California, United States, 90404
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Raffi Tachdjian
      • Tarzana, California, United States, 91356
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sanjay Vadgama
        • Contact:
        • Contact:
      • Upland, California, United States, 91786
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Amit Ishwarbha Patel
        • Contact:
        • Contact:
      • Woodland, California, United States, 95695
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rajan Merchant
        • Contact:
        • Contact:
    • Colorado
      • Aurora, Colorado, United States, 80238
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sunita Sharma
        • Contact:
        • Contact:
      • Colorado Springs, Colorado, United States, 80907
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Luke M Webb
        • Contact:
        • Contact:
      • Colorado Springs, Colorado, United States, 80923
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Eric Caplan
      • Denver, Colorado, United States, 80209
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ronina Covar
      • Lakewood, Colorado, United States, 80228
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dominic Titone
      • Wheat Ridge, Colorado, United States, 80033
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jeffrey Rumbyrt
        • Contact:
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06511
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Geoffrey L Chupp
        • Contact:
        • Contact:
    • Florida
      • Aventura, Florida, United States, 33180
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jaime Landman
      • Clearwater, Florida, United States, 33765-2103
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Francis J Averill
        • Contact:
        • Contact:
      • Fort Lauderdale, Florida, United States, 33316
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Frank Hull
        • Contact:
        • Contact:
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Eric Papierniak
      • Jacksonville, Florida, United States, 32209
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • James Davis Cury
        • Contact:
        • Contact:
      • Kissimmee, Florida, United States, 34746
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Fortune Alabi
        • Contact:
        • Contact:
      • Loxahatchee Groves, Florida, United States, 33470
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Neal Warshoff
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33125
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sara Llerena
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33126
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Guido Perez
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33144
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Yamirka Sanchez
      • Miami, Florida, United States, 33186
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jorge Paoli-Bruno
        • Contact:
        • Contact:
      • Miami, Florida, United States, 33172
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Luis Mas
      • Miami, Florida, United States, 33144
        • Completed
        • GSK Investigational Site
      • Miami Lakes, Florida, United States, 33014
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Agustin Rivas
      • Miami Lakes, Florida, United States, 33016
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jose Carpio
      • Miami Lakes, Florida, United States, 33125
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alberto Manzor
        • Contact:
        • Contact:
      • Miami Springs, Florida, United States, 33166
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Belkis Delgado
        • Contact:
        • Contact:
      • North Palm Beach, Florida, United States, 33408
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Alan Koterba
        • Contact:
        • Contact:
      • Orlando, Florida, United States, 32803
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kevin DeBoer
      • Orlando, Florida, United States, 32806
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Michael Anderson
        • Contact:
        • Contact:
      • Orlando, Florida, United States, 32819
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Marvin Heuer
      • Orlando, Florida, United States, 32827
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tarig Dinar
      • Pensacola, Florida, United States, 32504
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Okan Elidemir
        • Contact:
        • Contact:
      • Sebring, Florida, United States, 33870
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dennis Bassetti
      • Tallahassee, Florida, United States, 32308
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Ronald H. Saff
        • Contact:
        • Contact:
    • Georgia
      • Calhoun, Georgia, United States, 30701
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • John Trimble
        • Contact:
        • Contact:
      • Stonecrest, Georgia, United States, 30038
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rabahuddin Syed
    • Illinois
      • Northfield, Illinois, United States, 60093
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Steven R. Boas
      • Oak Park, Illinois, United States, 60301
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Rachana Shah
        • Contact:
        • Contact:
      • Skokie, Illinois, United States, 60077
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Giselle S Mosnaim
    • Indiana
      • Evansville, Indiana, United States, 47715
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Majed Koleilat
        • Contact:
        • Contact:
    • Kansas
      • Overland Park, Kansas, United States, 66210
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • William Lavery
        • Contact:
        • Contact:
    • Kentucky
      • Lexington, Kentucky, United States, 40509
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • William Greisner
        • Contact:
        • Contact:
      • Owensboro, Kentucky, United States, 42301
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Lee S Clore
        • Contact:
        • Contact:
    • Louisiana
      • Shreveport, Louisiana, United States, 71106
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Abraham Kaufman
    • Maine
      • Bangor, Maine, United States, 04401
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Paul Alan Shapero
        • Contact:
        • Contact:
    • Maryland
      • Baltimore, Maryland, United States, 21224
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mark C Liu
      • Chevy Chase, Maryland, United States, 20815
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mark D. Scarupa
        • Contact:
        • Contact:
      • White Marsh, Maryland, United States, 21162
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Manav Singla
        • Contact:
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jonathan Gaffin
      • Burlington, Massachusetts, United States, 01805
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nicole Grossman
      • New Bedford, Massachusetts, United States, 02740
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Shih
      • North Dartmouth, Massachusetts, United States, 02747
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Curtis J Mello
        • Contact:
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Njira Lugogo
        • Contact:
        • Contact:
      • Dearborn, Michigan, United States, 48124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Talal Khader
        • Contact:
        • Contact:
      • Flint, Michigan, United States, 48507
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Suresh Anne
        • Contact:
        • Contact:
      • Warren, Michigan, United States, 48088
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Oscar Franco Parodi Ortiz De Villate
      • West Bloomfield, Michigan, United States, 48332
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Syed Muhammad Talib Raza
    • Minnesota
      • Minneapolis, Minnesota, United States, 55454
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Charlene E McEvoy
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gailen Marshall
    • Missouri
      • Chesterfield, Missouri, United States, 63017
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Neil A Ettinger
        • Contact:
        • Contact:
      • Saint Charles, Missouri, United States, 63301
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Thomas M Siler
        • Contact:
        • Contact:
      • Saint Louis, Missouri, United States, 63110
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • H. James Wedner
    • Nebraska
      • Lincoln, Nebraska, United States, 68505
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Vinay Mehta
        • Contact:
        • Contact:
      • Omaha, Nebraska, United States, 68198-5990
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jill Poole
        • Contact:
        • Contact:
    • New Jersey
      • Brick, New Jersey, United States, 08724
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Bruce DeCotiis, Jr.
      • Northfield, New Jersey, United States, 08225
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mila Leong
      • Riverdale, New Jersey, United States, 07457
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jeffrey Weiss
      • Toms River, New Jersey, United States, 08755
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Vinay Sikand
    • New Mexico
      • Albuquerque, New Mexico, United States, 87108
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sally Fisher
        • Contact:
        • Contact:
      • Rio Rancho, New Mexico, United States, 87144
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sara Assaf
        • Contact:
        • Contact:
    • New York
      • Bronx, New York, United States, 10459-2417
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Samuel DeLeon
        • Contact:
        • Contact:
      • Bronx, New York, United States, 10467
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Golda Hudes
      • Brooklyn, New York, United States, 11215
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Saleem Shahzad
        • Contact:
        • Contact:
      • Horseheads, New York, United States, 14845
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Christopher A Smith
        • Contact:
        • Contact:
      • New Hyde Park, New York, United States, 11040
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jonathan Ilowite
        • Contact:
        • Contact:
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • David Cypcar
        • Contact:
        • Contact:
      • Huntersville, North Carolina, United States, 28078
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Thomas Stern
      • Wilmington, North Carolina, United States, 28401
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Mitchell D Lee
        • Contact:
        • Contact:
      • Winston-Salem, North Carolina, United States, 27157
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Wendy C Moore
        • Contact:
        • Contact:
      • Winston-Salem, North Carolina, United States, 27103
        • Completed
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Theresa Guilbert
      • Cincinnati, Ohio, United States, 45231
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David I Bernstein
      • Cleveland, Ohio, United States, 44106
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Kristie Ross
        • Contact:
        • Contact:
    • Oregon
      • Corvallis, Oregon, United States, 97330
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Roland Solensky
        • Contact:
        • Contact:
      • Happy Valley, Oregon, United States, 97086
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Sanjeev Jain
        • Contact:
        • Contact:
    • Pennsylvania
      • Altoona, Pennsylvania, United States, 16601
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael Zlupko
      • Bethlehem, Pennsylvania, United States, 18017
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Jeffrey C Bedrosian
        • Contact:
        • Contact:
      • DuBois, Pennsylvania, United States, 15801
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sandeep Bansal
      • Hershey, Pennsylvania, United States, 17033
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Timothy J. Craig
      • Philadelphia, Pennsylvania, United States, 19140
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kartik Shenoy
      • Pittsburgh, Pennsylvania, United States, 15241
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael J. Palumbo
      • Wyomissing, Pennsylvania, United States, 19610
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Daron Kahn
        • Contact:
        • Contact:
    • Rhode Island
      • Warwick, Rhode Island, United States, 02886
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • John F Zwetchkenbaum
        • Contact:
        • Contact:
    • South Carolina
      • Columbia, South Carolina, United States, 29204
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Laura Bagan Herpel
        • Contact:
        • Contact:
      • Rock Hill, South Carolina, United States, 29732
        • Completed
        • GSK Investigational Site
      • Spartanburg, South Carolina, United States, 29303
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Principal Investigator:
          • Farhan Siddiqui
        • Contact:
    • Tennessee
      • Hendersonville, Tennessee, United States, 37075
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Clyde Southwell
      • Knoxville, Tennessee, United States, 37909
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Karthik Krishnan
    • Texas
      • Amarillo, Texas, United States, 79124
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Constantine K Saadeh
        • Contact:
        • Contact:
      • Amarillo, Texas, United States, 79106
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Kalil Al-Nassir
      • Cypress, Texas, United States, 77429
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Dileep Puppala
        • Contact:
        • Contact:
      • Dallas, Texas, United States, 75225
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Barbara Baxter
      • Dallas, Texas, United States, 75235
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Tanya Martinez Fernandez
      • Dallas, Texas, United States, 75246
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Mark W Millard
      • Houston, Texas, United States, 77030
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Rodney J. Folz
      • Kerrville, Texas, United States, 78028
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dale E Mohar
      • McAllen, Texas, United States, 78503
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lenore DePagter
      • San Antonio, Texas, United States, 78207
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Christine Vidouria
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Robert M Ramirez
      • San Antonio, Texas, United States, 78258
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David A Marks
      • San Antonio, Texas, United States, 78215
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Leonel Reyes
        • Contact:
        • Contact:
      • Stafford, Texas, United States, 77477
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Sayyed Farhan Ali Jaffri
      • Waxahachie, Texas, United States, 75165
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Amir Khan
    • Utah
      • Murray, Utah, United States, 84107
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Andrew Smith
        • Contact:
        • Contact:
    • Virginia
      • Richmond, Virginia, United States, 23298
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Michael Schechter
      • Williamsburg, Virginia, United States, 23188
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Vijay Subramaniam
        • Contact:
        • Contact:
    • Washington
      • Bellingham, Washington, United States, 98225
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Elkayam
      • Seattle, Washington, United States, 98115
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Daniel H Petroni
        • Contact:
        • Contact:
    • Wisconsin
      • Greenfield, Wisconsin, United States, 53228
        • Recruiting
        • GSK Investigational Site
        • Principal Investigator:
          • Gary C Steven
        • Contact:
        • Contact:
      • Milwaukee, Wisconsin, United States, 53226
        • Recruiting
        • GSK Investigational Site
        • Contact:
        • Contact:
        • Principal Investigator:
          • Heidi T. Zafra

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Key inclusion criteria for study:

  • Adult and adolescent participants more than or equal to (>=)12 years of age, at the time of signing the informed consent/assent.
  • Participants who have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines.

  • Participants receiving either mepolizumab 100 milligrams (mg) or benralizumab 30 mg for >=12 months prior to screening and have a documented benefit to therapy assessed by either:

    (i) >=50% reduction in exacerbation frequency since initiating treatment, or (ii) >=50% reduction in maintenance OCS use since initiating treatment, or (iii) No exacerbations in the past 6 months whilst receiving anti-IL-5/5R therapy and an Asthma Control Questionnaire (ACQ)-5 score of less than or equal to (<=)1.5 at screening.

  • A well-documented requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS. The maintenance ICS dose must be >=440 micrograms (mcg) fluticasone propionate (FP) hydrofluoroalkane (HFA) product daily, or clinically comparable. Participants who are treated with medium dose ICS will also need to be treated with a LABA to qualify for inclusion.
  • Current treatment with at least one additional controller medication, besides ICS [for example (e.g.), LABA, LAMA, leukotriene receptor antagonist (LTRA), or theophylline].

Key exclusion criteria for study:

  • Participants with presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
  • A current malignancy or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis excluded prior to enrolment.
  • Participants who have received Omalizumab (Xolair), dupilumab (Dupixent) or reslizumab (Cinqair/Cinqaero) within 130 days prior to Visit 1.
  • Participants who have received any Monoclonal antibody (mAb) within 5 half-lives of Visit 1.
  • Corrected QT interval using Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at screening Visit 1.
  • Current smokers or former smokers with a smoking history of >=10 pack years (number of pack years equal to [number of cigarettes per day/20] times number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1.
  • Participants with allergy/intolerance to a mAb or biologic.

Key exclusion criteria for randomization:

  • Evidence of a clinically significant abnormality in the 12-lead electrocardiogram (ECG) over-read conducted at Screening Visit 1, based on the evaluation of the investigator, or QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block, at randomization Visit 2.
  • Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable. If the 8-week screening period has elapsed, then the participant should be considered a run-in failure.
  • Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment
Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
Biological: GSK3511294 (Depemokimab)
GSK3511294 (Depemokimab) will be provided in a single-use prefilled syringe (PFS).
Biological: Placebo
Placebo will be a sterile liquid formulation.
Drug: Standard of care (SoC)
Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
Device: Pre-filled Syringes (PFS)
PFS will include glass barrel with pre-staked needle and plunger.
Active Comparator: Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)
Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
Biological: Placebo
Placebo will be a sterile liquid formulation.
Drug: Standard of care (SoC)
Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
Device: Pre-filled Syringes (PFS)
PFS will include glass barrel with pre-staked needle and plunger.
Biological: Mepolizumab
Mepolizumab will be provided in a single-use PFS.
Biological: Benralizumab
Benralizumab will be provided in a single-use PFS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Annualized rate of clinically significant exacerbations over 52 weeks
Time Frame: Up to Week 52
Clinically significant exacerbations of asthma are defined by worsening of asthma which requires use of systemic corticosteroids and/or hospitalization and/or Emergency Department (ED) visit. Annualized rate of exacerbations will be calculated as number of exacerbations experienced by the participant divided by the length of time the participant is measured on.
Up to Week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weighted mean change from Baseline in St. George's Respiratory Questionnaire (SGRQ) total score
Time Frame: Baseline (Day 1) and up to Week 52
The SGRQ is a well-established instrument, comprising 51 questions designed to measure Quality of Life in participants with diseases of airway obstruction. Higher score indicates worse quality of life.
Baseline (Day 1) and up to Week 52
Weighted mean change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score
Time Frame: Baseline (Day 1) and up to Week 52
The ACQ-5 is a five-item questionnaire, which has been developed as a measure of participants' asthma control that can be quickly and easily completed. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze) over the previous week. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale. Higher score indicates more limitations.
Baseline (Day 1) and up to Week 52
Weighted mean change from Baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)
Time Frame: Baseline (Day 1) and up to Week 52
FEV1 is a measure of pulmonary function and is the maximum amount of air that can be forced out in one second after taking a deep breath. FEV1 will be measured using spirometry.
Baseline (Day 1) and up to Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Collaborators

Iqvia Pty Ltd

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 26, 2021

Primary Completion (Estimated)

September 26, 2025

Study Completion (Estimated)

September 26, 2025

Study Registration Dates

First Submitted

January 18, 2021

First Submitted That Met QC Criteria

January 18, 2021

First Posted (Actual)

January 22, 2021

Study Record Updates

Last Update Posted (Actual)

April 30, 2024

Last Update Submitted That Met QC Criteria

April 29, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 206785

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD for this study will be made available via the Clinical Study Data Request site.

IPD Sharing Time Frame

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD Sharing Access Criteria

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on GSK3511294 (Depemokimab)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe